Weishaar R E, Kobylarz-Singer D C, Steffen R P, Kaplan H R
Department of Pharmacology, Warner-Lambert/Parke Davis Pharmaceutical Research, Ann Arbor, Mich. 48105.
Circ Res. 1987 Oct;61(4):539-47. doi: 10.1161/01.res.61.4.539.
Ventricular muscle contains a low Km, cyclic AMP-specific form of phosphodiesterase (PDE III), which is believed to represent the site of action for several of new cardiotonic agents including imazodan (CI-914), amrinone, cilostamide, and enoximone. However, species differences in the inotropic response to these agents have raised questions about the relationship between PDE III inhibition and cardiotonic activity. The present study demonstrates that these differences can be accounted for by the presence of two subclasses of PDE III in ventricular muscle and variations in the intracellular localization of these two enzymes. For these experiments, PDE III was initially isolated from canine, guinea pig, and rat left ventricular muscle. The results demonstrate that canine left ventricular muscle contains two functional subclasses of PDE III: an imazodan-sensitive form, which is membrane bound, and an imazodan-insensitive form, which is soluble. Although only weakly inhibited by imazodan, this latter enzyme is potently inhibited by the selective PDE III inhibitors, Ro 20-1724 and rolipram. Guinea pig ventricular muscle also contains the imazodan-sensitive subclass of PDE III. Unlike canine left ventricle, however, thi enzyme is soluble in the guinea pig. No membrane-bound subclass of PDE III was observed in the guinea pig. Rat left ventricle possesses only the soluble form of PDE III, which apparently represents a mixture of the imazodan-sensitive and imazodan-insensitive subclasses of PDE III. Measurement of in vivo contractility in these three species showed that imazodan exerts a potent positive inotropic effect only in the dog, in which the imazodan-sensitive subclass of PDE III is membrane bound.(ABSTRACT TRUNCATED AT 250 WORDS)
心室肌含有一种低Km、对环磷酸腺苷具有特异性的磷酸二酯酶(PDE III),据信它是包括咪唑旦(CI - 914)、氨力农、西洛他唑和依诺昔酮在内的几种新型强心剂的作用位点。然而,这些药物在不同物种中产生的变力性反应差异引发了关于PDE III抑制与强心活性之间关系的疑问。本研究表明,这些差异可归因于心室肌中存在PDE III的两个亚类以及这两种酶在细胞内定位的变化。在这些实验中,PDE III最初是从犬、豚鼠和大鼠的左心室肌中分离出来的。结果表明,犬左心室肌含有PDE III的两个功能亚类:一种对咪唑旦敏感的形式,它与膜结合;另一种对咪唑旦不敏感的形式,它是可溶的。尽管后者仅被咪唑旦微弱抑制,但它被选择性PDE III抑制剂Ro 20 - 1724和咯利普兰强烈抑制。豚鼠心室肌也含有对咪唑旦敏感的PDE III亚类。然而,与犬左心室不同的是,这种酶在豚鼠中可溶。在豚鼠中未观察到与膜结合的PDE III亚类。大鼠左心室仅具有PDE III的可溶形式,它显然代表了对咪唑旦敏感和不敏感的PDE III亚类的混合物。对这三个物种的体内收缩性测量表明,咪唑旦仅在犬中发挥强大的正性肌力作用,在犬中对咪唑旦敏感的PDE III亚类与膜结合。(摘要截选至250词)